92286-43-6 Usage
General Description
3-(4-chlorophenyl)-5-(3-chloropropyl)-1,2,4-oxadiazole is a chemical compound with a molecular formula C11H10Cl2N2O. It is a heterocyclic organic compound containing an oxadiazole ring. It is used in research and development activities, particularly in the pharmaceutical and agrochemical industries. The compound has potential applications as a building block for the synthesis of various biologically active molecules, such as insecticides, fungicides, and pharmaceutical drugs. Additionally, it has been studied for its potential use as a fluorescent probe for detecting anions in biological systems. The compound's unique structure and properties make it a valuable tool for scientific and industrial applications.
Check Digit Verification of cas no
The CAS Registry Mumber 92286-43-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,2,2,8 and 6 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 92286-43:
(7*9)+(6*2)+(5*2)+(4*8)+(3*6)+(2*4)+(1*3)=146
146 % 10 = 6
So 92286-43-6 is a valid CAS Registry Number.
InChI:InChI=1/C11H10Cl2N2O/c12-7-1-2-10-14-11(15-16-10)8-3-5-9(13)6-4-8/h3-6H,1-2,7H2
92286-43-6Relevant articles and documents
Synthesis and Biological Evaluation of Sigma-1 (σ1) Receptor Ligands Based on Phenyl-1,2,4-oxadiazole Derivatives
Cao, Xudong,Yao, Zhongyuan,Dou, Fei,Zhang, Yifang,Qiu, Yinli,Zhao, Song,Xu, Xiangqing,Liu, Xin,Liu, Bi-Feng,Chen, Yin,Zhang, Guisen
, (2019/02/26)
In this study, a series of phenyl-1,2,4-oxadiazole derivatives were synthesized and evaluated for anti-allodynic activity. Structure–activity relationship studies identified 1-{4-[3-(2,4-dichlorophenyl)-1,2,4-oxadiazol-5-yl]butyl}piperidine (39) with excellent affinity for the σ1 receptor and selectivity for the σ2 receptor, with poor activity to other central nervous system neurotransmitter receptors and transporters associated with pain. Compound 39 exhibited dose-dependent efficacy in suppressing the formalin-induced flinching and attenuating mechanical allodynia in chronic constriction injury-induced neuropathic rats. These results suggest that compound 39 exerts potent antihyperalgesic activity and could be considered as a promising candidate for treating neuropathic pain.
